Letters to the Editor

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Information Services, University of Pennsylvania
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY; Comprehensive Bone Marrow Failure Center, Children’s Hospital of Philadelphia
Comprehensive Bone Marrow Failure Center, Children’s Hospital of Philadelphia, Philadelphia, PA; Department of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA; Comprehensive Bone Marrow Failure Center, Children’s Hospital of Philadelphia
Haematologica Early view Apr 18, 2024 https://doi.org/10.3324/haematol.2024.285275